PRIMACOR Drug Patent Profile
✉ Email this page to a colleague
When do Primacor patents expire, and when can generic versions of Primacor launch?
Primacor is a drug marketed by Sanofi Aventis Us and is included in two NDAs.
The generic ingredient in PRIMACOR is milrinone lactate. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the milrinone lactate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Primacor
A generic version of PRIMACOR was approved as milrinone lactate by FRESENIUS KABI USA on May 28th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PRIMACOR?
- What are the global sales for PRIMACOR?
- What is Average Wholesale Price for PRIMACOR?
Summary for PRIMACOR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 131 |
| Clinical Trials: | 11 |
| Patent Applications: | 3,879 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | PRIMACOR at DailyMed |
Recent Clinical Trials for PRIMACOR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mahidol University | Phase 2 |
| Zagazig University | Phase 4 |
| University of Kansas Medical Center | Phase 1 |
US Patents and Regulatory Information for PRIMACOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | PRIMACOR | milrinone lactate | INJECTABLE;INJECTION | 019436-001 | Dec 31, 1987 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER | milrinone lactate | INJECTABLE;INJECTION | 020343-003 | Aug 9, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER | milrinone lactate | INJECTABLE;INJECTION | 020343-001 | Aug 9, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER | milrinone lactate | INJECTABLE;INJECTION | 020343-002 | Aug 9, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER | milrinone lactate | INJECTABLE;INJECTION | 020343-004 | Aug 9, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PRIMACOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | PRIMACOR | milrinone lactate | INJECTABLE;INJECTION | 019436-001 | Dec 31, 1987 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PRIMACOR
See the table below for patents covering PRIMACOR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| France | 2553767 | 1-PYRIDINYL-2-(DIALKYL-AMINO) ETHENYL ALKYL CETONES ET LEUR PROCEDE DE PREPARATION | ⤷ Sign Up |
| Austria | 379386 | ⤷ Sign Up | |
| Spain | 506342 | ⤷ Sign Up | |
| Sweden | 451722 | 1-PYRIDINYL-2-(DIALKYLAMINO)-ETENYL-ALKYLKETONER ANVENDBARA SOM INTERMEDIATER VID FRAMSTELLNING AV PYRIDINONER MED KARDIOTONISKA EGENSKAPER | ⤷ Sign Up |
| Spain | 500726 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
